Skip to content

Clinical efficacy of neuromodulation intervention based on combined peripheral-central stimulation on upper limb motor dysfunction in stroke patients

Clinical efficacy of neuromodulation intervention based on combined peripheral-central stimulation on upper limb motor dysfunction in stroke patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079867
Enrollment
Unknown
Registered
2024-01-15
Start date
2024-01-15
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Central Electrical Stimulation Group:Peripheral magnetic stimulation + central electrical stimulation
Central magnetic stimulation group:Peripheral magnetic stimulation + central magnetic stimulation
control group:Peripheral magnetic stimulation

Sponsors

Department of Rehabilitation Medicine, Golden Hospital, The First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the "Guidelines for the Diagnosis and Treatment of Stroke" and diagnosed as stroke with upper limb motor dysfunction by MRI or CT. (2) Upper limb muscle tone modified Ashworth scale rating of ?1+. (3) First episode, or no residual upper extremity motor dysfunction after the last episode. (4) No gender restrictions, aged 18-80 years old, with a duration of ischaemic stroke from 2 weeks to 6 months and haemorrhagic stroke from 1 month to 6 months. (5) No severe cognitive impairment, aphasia, or hearing loss. (6) No physical disability, motor dysfunction, or sensory dysfunction prior to the onset of stroke. (7) Willing to participate in the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with cranial defects in the affected hemisphere, subarachnoid haemorrhage, cavernous cerebral infarction, brain tumour, cerebral aneurysm, traumatic brain injury, etc., as well as patients with severe hydrocephalus, large cerebral haematoma, and patients with deterioration of the condition during the progressive stage of stroke. (2) With serious diseases of heart, lungs, liver, kidney and other internal organs, unable to tolerate the treatment. (3) Previous motor dysfunction caused by other diseases, such as multiple sclerosis, myasthenia gravis, etc. (4) Have a history or family history of seizures, or are taking medications that lower the seizure threshold or antiepileptic drugs. (5) Metal foreign bodies in the skull, face, cervical spine, or around the clavicle on the affected side. (6) Have an implanted electronic device such as a pacemaker, cochlear implant, or related medical pumps. (7) Recent severe headache or frequent headache (8) Female subjects who are pregnant, breastfeeding, or likely to become pregnant. (9) Participated or is participating in other intervention studies in the last week

Design outcomes

Primary

MeasureTime frame
Upper Extremity Section of the Fugl-Meyer Scale (FMA-UE);

Secondary

MeasureTime frame
Modified Barthel Index (MBI);Motor Assessment Scale (MAS);functional near-infrared spectroscopy,fNIRS;

Countries

China

Contacts

Public ContactZhong Yanbiao

Department of Rehabilitation Medicine, Golden Hospital, The First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, China

zhongyb2010@163.com+86 182 0182 6956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026